BCL-2 family regulation by the 20S proteasome inhibitor bortezomib

被引：129

作者：

Fennell, D. A. ^{[1
]}

Chacko, A. ^{[1
]}

Mutti, L. ^{[2
]}

机构：

[1] Queens Univ Belfast, Thorac Oncol Res Grp, Ctr Canc Res & Cell Biol, Belfast, Antrim, North Ireland

[2] Med Gen Lab Oncol Clin, Vercelli, Italy

来源：

ONCOGENE | 2008年 / 27卷 / 09期

关键词：

mitochondria; proteasome; BAX; BAK; BIM; NOXA;

D O I：

10.1038/sj.onc.1210744

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Bortezomib (Velcade, PS341) was licensed in 2003 as a first-in-class 20S proteasome inhibitor indicated for treatment of multiple myeloma, and is currently being evaluated clinically in a range of solid tumours. The mechanisms underlying its cancer cell toxicity are complex. A growing body of evidence suggests proteasome inhibition-dependent regulation of the BCL-2 family is a critical requirement. In particular, the stabilization of BH3-only proteins BIK, NOXA and BIM, appear to be essential for effecting BAX- and BAK-dependent cell death. These mechanisms are reviewed and the implications for favourable novel drug interactions are highlighted.

引用

页码：1189 / 1197

页数：9

共 50 条

[31] Regulation of apoptosis by Bcl-2 family proteins
Burlacu, A
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2003, 7 (03) : 249 - 257
[32] Redox control of 20S proteasome
Friguet, B
Bulteau, AL
Conconi, M
Petropoulos, I
REDOX CELL BIOLOGY AND GENETICS, PT B, 2002, 353 : 253 - 262
[33] The Contribution of the 20S Proteasome to Proteostasis
Deshmukh, Fanindra Kumar
Yaffe, Dana
Olshina, Maya A.
Ben-Nissan, Gili
Sharon, Michal
BIOMOLECULES, 2019, 9 (05)
[34] Autocatalytic processing of the 20S proteasome
Seemuller, E
Lupas, A
Baumeister, W
NATURE, 1996, 382 (6590) : 468 - 470
[35] Structure and assembly of the 20S proteasome
W. L. H. Gerards
W. W. de Jong
W. Boelens
H. Bloemendal
Cellular and Molecular Life Sciences CMLS, 1998, 54 : 253 - 262
[36] Structure and assembly of the 20S proteasome
Gerards, WLH
de Jong, WW
Boelens, W
Bloemendal, H
CELLULAR AND MOLECULAR LIFE SCIENCES, 1998, 54 (03) : 253 - 262
[37] Molecular modeling on porphyrin derivatives as β5 subunit inhibitor of 20S proteasome
Arba, Muhammad
Nur-Hidayat, Andry
Ruslin
Yusuf, Muhammad
Sumarlin
Hertadi, Rukman
Wahyudi, Setyanto Tri
Surantaadmaja, Slamet Ibrahim
Tjahjono, Daryono H.
COMPUTATIONAL BIOLOGY AND CHEMISTRY, 2018, 74 : 230 - 238
[38] The combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide
O'Connor, OA
Smith, EA
Toner, LE
Teruya-Feldstein, J
Frankel, S
Rolfe, M
Wei, XH
Liu, SJ
Marcucci, G
Chan, KK
Chanan-Khan, A
CLINICAL CANCER RESEARCH, 2006, 12 (09) : 2902 - 2911
[39] Ubiquitin-proteasome pathway-mediated regulation of the Bcl-2 family: effects and therapeutic approaches
Tang, Galvin Le Qian
Lai, Jolin Xiao Hui
Pervaiz, Shazib
HAEMATOLOGICA, 2024, 109 (01) : 33 - 43
[40] Regulation of apoptosis by members of the ICE family and the Bcl-2 family
Miller, DK
ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 31, 1996, 31 : 249 - 268

← 1 2 3 4 5 →